The Infrastructure Alpha:

India's Healthtech Claims Infrastructure

Moving Capital from Distribution to Claims & Operations Rails

Ujan Banerjee

Harris School of Public Policy, University of Chicago �January 2026

Executive Summary

Confidential

1

Opportunity: India's health insurance GWP reached ~$14B in FY25, growing at ~15% CAGR toward $30–46B by 2030. The removal of 18% GST on individual health premiums (Sep 2025) and PM-JAY's expansion to ~1Cr gig workers are injecting millions of first-time, price-sensitive buyers into a system built for corporate group plans. An estimated 400M Indians, the 'Missing Middle', remain entirely uninsured.

�

Bottleneck: This volume surge collides with a new regulatory reality. IRDAI now mandates 1-hour pre-authorization and 3-hour cashless settlement. Legacy TPAs operate manual, PDF-based workflows designed for 24-hour cycles. Only ~300 of India's 54,000 hospitals are connected to the National Health Claims Exchange (NHCX). Claims worth ~$310M were rejected in FY24 alone, up 19% YoY. The infrastructure cannot absorb the incoming volume.

�

Thesis: Capital must shift from Distribution (selling policies: Red Ocean, high CAC, commoditizing) to Infrastructure (processing claims: Blue Ocean, regulatory moat, recurring revenue). We target B2B middleware companies: AI adjudication engines, hospital RCM SaaS, and financing rails that serve as the unavoidable operating system for India's health claims economy.

�

Target: Healspan, a hospital-side cashless claims SaaS platform targeting Tier 2/3 hospitals. Pre-seed stage ($508K raised), entering at seed valuation ($6–10M cap). The company's pure SaaS model and focus on the underserved 40,000+ non-metro hospitals position it to capture the NHCX digitization wave, though significant competitive and capital risks exist relative to better-funded peers.

Market Overview: India Health Insurance

Confidential

2

Source: IRDAI, PIB (Mar 2026)

Health Insurance Penetration: 0.35% of GDP (vs. 1.8% Taiwan, 0.93% Australia, 0.78% China)

'Missing Middle': ~400M uninsured Indians earning $6K–$14K/yr (NITI Aayog). Too rich for PM-JAY, too poor for private retail

Retail vs. Group Split: 44% retail (~$5.6B) / 56% group (~$7.2B). Retail is the faster-growing segment

Claims Settled (FY25): 32.6M total, 87.5% settlement ratio by count. Record high

Projected 2030 GWP: $30–46B (11–15% CAGR). Range reflects BCG, Grand View Research, IBEF estimates

GST Impact (Sep 2025): 18% GST eliminated on individual premiums → ~15–18% effective price reduction. Group still taxed at 18%

Regulatory Catalysts

Confidential

3

The Claims Infrastructure Problem

Confidential

4

The volume-speed collision: 32.6M claims were settled in FY25. With GST removal, gig worker coverage, and Bima Vistaar in pipeline, claims volume is projected to grow 20–25% in the near term. The IRDAI now requires these claims processed within 3 hours. Legacy TPAs designed for 24-hour turnarounds, using manual PDF review, phone-based coordination, and paper trails, cannot meet this standard at scale.

�

~$310M

Claims rejected in FY24

(up 19% YoY)

25%

First-attempt full approval rate

(75% rejected or partially denied)

16%

Hospitals with AI/automation

in finance operations

The resulting 'Compliance vs. Cost' Trap: Insurers who delay claims face regulatory penalties and reputational damage. Those who rush approvals face margin erosion and MLR blowouts. The only exit is infrastructure that decouples processing volume from headcount: automated adjudication, real-time pricing intelligence, and digital hospital connectivity.

�

NHCX is the unlock, but hospital onboarding is the bottleneck. All 47+ insurers are integrated. Only ~300 of 54,000 hospitals are connected. The race to become the hospital-side interface to NHCX is wide open. This is where the investable opportunity sits.

Infrastructure TAM: Digitizing the Expense Ratio

Confidential

5

$30–46B

2030 GWP

$6–9B

Operating Costs

(~20% of GWP)

$2–4B

Infra Revenue Pool

(Claims SaaS, Financing,

API middleware)

$22B

TPA Market by 2033

(IMARC)

→

→

→

Core thesis: As average ticket sizes drop for the Missing Middle, the $6–9B operating cost pool must shift from human intermediaries to API-first infrastructure. We invest in the companies that charge a fee on every rupee flowing through the system without taking balance sheet risk.

US RCM Valuation Comps

Competitive Landscape: Claims Infrastructure Layer

Confidential

6

Adjacent (Distribution): Zopper ($25M Series D): embedded API middleware | Riskcovry ($4.5M Ser A): B2B embedded infra | Plum (~$23M Ser B, $140M val): group health benefits | Onsurity ($21M Ser B-II): SME health | Artivatic.ai (acquired by RenewBuy ~$10M): AI underwriting

Legacy TPAs: Medi Assist (NSE-listed, ~$101M TTM revenue, ~20% market share, acquired Paramount for ~$49M) | MDIndia (~$42M revenue, 19K hospitals) | ~21–30 licensed TPAs handle 69–72% of all claims. Consolidation underway; small TPAs face disintermediation from NHCX standardization.

Investment Framework

Confidential

7

Core Thesis: Shift capital from Distribution (Red Ocean: high CAC, commoditizing, PolicyBazaar/PhonePe dominant) to Infrastructure (Blue Ocean: regulatory moat, per-transaction revenue, defensible switching costs). The 400M Missing Middle creates volume that manual legacy rails cannot absorb.

From the landscape, three companies map to 'High Conviction' across distinct deficits:��Vitraya (Intelligence Layer): Strong NHCX nativity. Solves the Trust Deficit via AI-led fraud detection. But already at Series A+ valuation.�Care.fi (Capital Layer): Exceptional data monetization via NBFC. Solves the Liquidity Deficit. But balance-sheet heavy model.�Healspan (Operations Layer): Exceptional provider stickiness target. Solves the Access Deficit for Tier 2/3 hospitals. Pure SaaS, seed valuation entry. The optimal venture bet for this cycle, with caveats.

Target: Healspan – Company Overview

Confidential

8

Why Healspan Fits the Thesis

1. Forced Adoption Tailwind�

40,000+ Tier 2/3 hospitals must digitize for NHCX compliance or risk losing cashless empanelment. Healspan targets the 'WhatsApp Generation' of hospital clerks: mobile-first, minimal-click design that reduces the skill barrier to near zero.

2. Pure SaaS Economics�

Zero marginal cost software vs. ops-heavy competitors (ClaimBuddy deploys staff at hospital desks; Bima Garage runs a claims BPO). Healspan can price 50% below service-heavy rivals while maintaining software margins. High stickiness once installed.

3. Seed Valuation Entry�

Entering at $6–10M cap vs. Vitraya (Series A+, $12.8M raised), Care.fi (Series A, Peak XV). Significant discount to intelligence-layer peers. Capital is the sole constraint on growth.

4. Right Segment�

IHX/Perfios focuses on the exchange layer (insurer-side). Vitraya sells to large insurers. ClaimBuddy concentrates on metro hospitals. Healspan's Tier 2/3 niche is large, fragmented, and underserved by incumbents.

Key Risks & Mitigants

Confidential

9

Deal Dynamics & Return Profile

Confidential

10

Entry

Valuation arbitrage: Entry at seed ($6–10M cap) vs. intelligence-layer peers priced at Series A+. Post-regulation (NHCX live) but pre-adoption (~300 of 54K hospitals). Captures steepest part of growth curve.�

US RCM comps support exit multiples: Waystar at 5–6x revenue, R1 RCM taken private at 2.5x, GeBBS (Indian-origin) sold for $850M to EQT. Average RCM deal multiple 2021–24: 6.1x EV/Revenue.

Exit Vectors

Value Creation Plan

Network Access: Facilitate pilot partnerships with Tier 1 hospital chains to validate enterprise use case. �Regulatory Shielding: Policy expertise to ensure NHCX/IRDAI compliance as mandates evolve. �Talent: Hire VP Sales to scale founder-led motion into a repeatable engine. Target: 2,000 hospitals in 18 months.

Conclusion

Confidential

11

Healspan is the only player treating India's 'Missing Middle' hospitals as a software opportunity rather than a service burden, capitalizing on a regulatory shock to become the operating system for India's healthcare hinterland.�

The structural case is strong: ~$15B in premiums growing at double digits, 32.6M claims annually, ~$310M in rejections as pure inefficiency, regulatory mandates forcing digital-first cashless processing, and 800M ABHA health IDs creating the identity layer.��The entry is attractive: Seed valuation ($6–10M cap) with meaningful ownership. Post-regulation but pre-adoption timing. US RCM comps at 5–6x revenue support significant exit multiples.��The primary risk is execution: At $508K raised vs. Vitraya ($12.8M), Care.fi ($10.6M), and IHX/Perfios (30K hospitals), Healspan is dramatically under-capitalized relative to the competition. The investment thesis hinges on whether a seed round can fund a 'land grab' across 40,000+ Tier 2/3 hospitals before better-funded players move downstream.

54,000

Hospitals in India

~300

Connected to NHCX

99.4%

Still need digitization

$30–46B

Market by 2030